ALX Oncology Holdings ALXO 深 沪
交易中 12-16 10:19:56 美东时间
1.48
+0.080
+5.71%
华盛通- 最 高1.50
- 今 开1.38
- 成交量 2.48万股
- 最 低 1.37
- 昨 收 1.40
- 总市值 7909.71万
- 52周最高 2.27
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.404
- 委 比 20.00%
- 总股本 5344.40万
- 历史最高 117.45
- 量 比 1.81
- 振 幅 9.29%
- 历史最低 0.404
- 每 手 1
- 风险率 0.49%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting
ALX Oncology announced positive Phase 2 data showing evorpacept combined with R² achieved a 92% complete response rate in untreated indolent non-Hodgkin lymphoma patients, significantly higher than the historical 50% for R² alone. The regimen was well-tolerated, with a 100% overall response rate and promising 1-year survival rates. Further evaluation of minimal residual disease eradication is pending longer follow-up. The study was presented at t...
12-07 13:00
ALX Oncology to Present at Upcoming Investor Conferences
ALX Oncology announced that its leadership will participate in the Jefferies Global Healthcare Conference in London and the Piper Sandler 37th Annual Global Healthcare Conference in New York. The Jefferies event will be on November 19, 2025, at 11:30 AM GMT, and the Piper Sandler event on December 3, 2025, at 9:30 AM EST, both in Fireside Chat format. Webcasts are available on the company's website, and replays will be archived for 90 days. ALX O...
11-18 16:00
ALX Oncology anticipates $2B–$4B HER2/CD47 breast cancer market opportunity while advancing biomarker-driven strategies
Earnings Call Insights: ALX Oncology Holdings Inc. (ALXO) Q3 2025 Management View CEO Jason Lettmann opened the call by highlighting progress in the evorpacept and ALX2004 clinical programs, emphasizi...
11-08 04:57
ALX Oncology Holdings Q3 Adj. EPS $(0.36) Beats $(0.37) Estimate
ALX Oncology Holdings (NASDAQ:ALXO) reported quarterly losses of $(0.36) per share which beat the analyst consensus estimate of $(0.37) by 1.91 percent. This is a 20 percent increase over losses of $(0.45) per share from
11-07 21:17
Earnings Scheduled For November 7, 2025
Companies Reporting Before The Bell • Kiora Pharmaceuticals (NASDAQ:KPRX) is pr...
11-07 19:11
ALX Oncology Presents Preclinical Data And Trial Design For Ongoing Phase 1 Clinical Trial For ADC Candidate, ALX2004, In Two Poster Presentations At 2025 AACR-NCI-EORTC Conference
-Two poster presentations showcase best- and first-in-class potential of ALX2004, a novel, antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors-Robust body of preclinical data supports ALX2004
10-24 00:31
ALX Oncology Announces Preclinical Data and Phase 1 Trial-in-Progress Presentations of ALX2004, a Novel EGFR-Targeted ADC, at 2025 AACR-NCI-EORTC Conference
ALX Oncology presented preclinical data and Phase 1 trial design for its novel ADC, ALX2004, targeting EGFR-expressing solid tumors, at the 2025 AACR-NCI-EORTC Conference. ALX2004 demonstrates potent anti-tumor activity and a favorable safety profile, addressing limitations of earlier ADCs. Initial safety data from the first-in-human trial is expected in early 2026. The company highlighted ALX2004's unique design, including a proprietary linker-p...
10-23 16:30
ALX Oncology to Present Updated Data from Phase 2 ASPEN-06 Trial, Highlighting CD47 Expression as a Predictive Biomarker in HER2+ Gastric Cancer, at 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting
ALX Oncology will present updated Phase 2 ASPEN-06 trial data at the SITC 2025 Annual Meeting, highlighting CD47 overexpression as a key predictive biomarker for response to evorpacept in HER2+ gastric cancer. The trial evaluates evorpacept in combination with HERCEPTIN, CYRAMZA, and paclitaxel for patients with previously treated HER2-positive advanced gastric or gastroesophageal junction cancer. The study enrolled 127 patients and aims to demon...
10-03 13:05
ALX Oncology Announces Management Changes Amidst Nasdaq Compliance
The latest update is out from ALX Oncology Holdings ( ($ALXO) ). On September 1...
09-12 20:57
ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer
ALX Oncology announced that Barbara Klencke, M.D., will serve as Interim Chief Medical Officer, while Alan Sandler, M.D., steps down from the role to return to the Board of Directors. Dr. Klencke, with over 30 years of experience in oncology drug development, will lead the Company’s clinical programs, including evorpacept and ALX2004.
09-12 12:30
